Efficacy of Dose Escalation Regimen Proven
Accelerating U.S. Market Expansion with Data-Driven Strategy

Celltrion announced on April 2 that a paper detailing the results of a post-hoc analysis from the global Phase 3 clinical trial of 'Zympendra' (the U.S. brand name for Remsima SC), the world’s only infliximab subcutaneous (SC) formulation therapy, has been published in the latest issue of the international journal 'Inflammatory Bowel Diseases (IBD)'.

Celltrion Jimpentra. Celltrion

Celltrion Jimpentra. Celltrion

View original image

The international journal IBD is the official publication of the Crohn's & Colitis Foundation, the world’s largest nonprofit dedicated to supporting patients and research on inflammatory bowel diseases. The journal’s impact factor ranks within the top 20% in its field, earning high credibility in the area of inflammatory bowel diseases.


The newly released study presents the post-hoc analysis results from the Zympendra global Phase 3 trial conducted over 102 weeks. The clinical efficacy was analyzed in Crohn’s disease (CD) and ulcerative colitis (UC) patients who experienced loss of response during maintenance therapy with Zympendra 120mg every other week, upon increasing the dose to 240mg.


According to the study results, over 80% of CD and UC patients who received the increased dose recovered their response, with the majority showing early recovery of response within eight weeks after dose escalation. Notably, patients who exhibited this early recovery also demonstrated favorable outcomes in various long-term efficacy indicators, supporting that dose escalation plays a key role in enhancing treatment persistence.


This study confirms that dose escalation with Zympendra can serve as a practical treatment option for inflammatory bowel disease patients struggling with loss of drug response. With this, Celltrion has established clinical evidence for realizing 'treatment optimization' through personalized prescriptions for patients.


Since the launch of Zympendra, Celltrion has continuously strengthened its marketing by presenting diverse clinical data through major global conferences and journals. In addition to this dose escalation regimen, the company has secured a wide range of efficacy data, including treatment response by disease location, predictors of response loss, endoscopic and histological remission rates, and long-term immunogenicity effects. As more multifaceted data are confirmed, medical professionals’ trust in and preference for prescribing the product are expected to further increase.


Zympendra’s strong clinical foundation and rising preference are translating into tangible prescription results. In particular, as of January this year, Zympendra recorded its highest-ever prescription volume—more than tripling compared to the same period last year and surpassing the entire first quarter total of last year in just one month, demonstrating overwhelming growth. The company expects that with the addition of medical efficacy data, expanded local marketing, and enhanced reimbursement coverage, the product’s prescription market share will continue to accelerate in the future.



A Celltrion representative stated, "With the efficacy results of Zympendra dose escalation published in the official journal of the prestigious Crohn's & Colitis Foundation, we have once again demonstrated the product’s competitiveness. Based on ongoing accumulation of clinical evidence in the growing U.S. market, we will do our utmost to ensure that more inflammatory bowel disease patients can benefit from Zympendra’s outstanding therapeutic effects."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing